Cryo-Cell International Inc. Common Stock (CCEL)
Stock · AMEX · Health Care
$4.42as of 10/16/2026
Price chart
Active signals
CCEL Signal Track Record
How signals performed across all stocks →What CCEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -4.2% | 35% | October 1, 2026 |
| Bollinger Band Breakdown | 24 | +2.9% | 58% | September 21, 2026 |
| Bollinger Band Breakout | 22 | -2.8% | 41% | August 20, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +3.5% | 59% | August 5, 2026 |
| Any 20-session window (baseline) | -3.2% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CCEL
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing…
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Employees
- 72
- Website
- www.cryo-cell.com/
Fundamentals
- 1-day range
- $3.65$4.46
- Market cap
- $28.78M
- P/E (trailing)
- —
- P/E (forward)
- 182.50
- EPS (trailing)
- $-0.31
- Dividend yield
- 17.19%
- Beta
- 0.60
- Avg. volume
- 24.8K
- Ex-dividend date
- May 21, 2025
- Dividend pay date
- May 30, 2025
How Cryo-Cell International Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Cryo-Cell International Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CCELCryo-Cell International Inc. Common Stock$4.42▲ 21.10%Market cap $28.78MP/E —$2.72$4.9
- MGRXMangoceuticals Inc. Common Stock$0.29▼ 9.66%Market cap $10.31MP/E —$0.162$2.75
- NIVFNewGenIvf Group Limited Class A Ordinary Shares$0.279▲ 11.60%Market cap $3.36MP/E 0.18$0.1722$24,624
- NIVFWNewGenIvf Group Limited Warrants$0.0123▼ 11.51%Market cap $102.7KP/E —$0.0086$0.09
- PARKPark Dental Partners Inc. Common Stock$18.95▼ 1.33%Market cap $96.71MP/E —$9.53$26.79
- VMDViemed Healthcare Inc. Common Shares$9.48▼ 2.77%Market cap $362.60MP/E 25.72$6.05$12.61
- AGLagilon health inc. Common Stock$85.12▼ 3.76%Market cap $1.45BP/E —$7.48$133.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CCEL Cryo-Cell International Inc. Common Stock | $28.78M | — | $4.42 | ▲ 21.10% | $2.72$4.9 |
| MGRX Mangoceuticals Inc. Common Stock | $10.31M | — | $0.29 | ▼ 9.66% | $0.162$2.75 |
| NIVF NewGenIvf Group Limited Class A Ordinary Shares | $3.36M | 0.18 | $0.279 | ▲ 11.60% | $0.1722$24,624 |
| NIVFW NewGenIvf Group Limited Warrants | $102.7K | — | $0.0123 | ▼ 11.51% | $0.0086$0.09 |
| PARK Park Dental Partners Inc. Common Stock | $96.71M | — | $18.95 | ▼ 1.33% | $9.53$26.79 |
| VMD Viemed Healthcare Inc. Common Shares | $362.60M | 25.72 | $9.48 | ▼ 2.77% | $6.05$12.61 |
| AGL agilon health inc. Common Stock | $1.45B | — | $85.12 | ▼ 3.76% | $7.48$133.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into Mondaybenzinga · 10/12/2026
Insider Activity
Insider Actions →- David Portnoy · August 5, 2026 · J600.2K @ $1.33
- Jill M. Taymans · May 28, 2026 · Option Exercise7.5K @ $3.1
Institutional Ownership
March 31, 2026
- Total shares held
- 509.3K
- Total value held
- $1.81M
- Institutional holders
- 10
- Unknown165.3K
- Unknown161.5K
- Unknown111.0K
- Unknown43.6K
- Unknown14.0K
- Unknown10.0K
- Unknown2.5K
- Unknown672
- Unknown601
- Unknown100
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates
Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates. Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.